Market Newsdesk

Singapore, April 13, 2021 (GLOBE NEWSWIRE) — Finxflo, the world’s first hybrid DeFi/CeFi liquidity aggregator, today announced its partnership with Crypto.com, the pioneering payments and cryptocurrency platform, to serve as the platform’s first liquidity provider. The partnership between Crypto.com and Fearless Legends Pte. Ltd (trading as Finxflo), will incorporate Crypto.com’s added liquidity to increase transaction volume, and simultaneously mitigate market volatility to ensure a seamless experience for Finxflo users.

As the DeFi sector gains momentum, interest in liquidity aggregators has grown proportionally, with aggregators making up roughly 20% of decentralized trading volumes over the past year, according to Messari. Liquidity aggregators offer a slew of benefits to traders, including deeper liquidity pools and price execution. Crypto.com joining Finxflo as the first liquidity provider deepens Finxflo’s liquidity pool, and offers users an optimized trading experience.

“Crypto.com is a transcendent platform in the space with over 10 million users, and we are thrilled to announce them as our first liquidity provider,” commented James Gillingham, CEO of Finxflo. “Partnering with this proven liquidity provider not only cements Finxflo as a market-leader in liquidity, but also helps us on our mission to provide our users with the best possible trade options.”

Retail participation is a primary catalyst in the latest bull market trend. As new cryptocurrency traders enter the market, Finxflo aims to provide a platform that protects users against issues stemming from low liquidity pools like exchange instability, slow transaction times, and market manipulation. Finxflo’s innovative hybrid model is designed to offer the best prices for CeFi and DeFi protocols, and alleviates aforementioned problem areas by presenting users trade options across 25+ exchanges from a single interface — maximizing prices and returns.

“We want to eliminate the hurdles associated with crypto trading, and streamline the experience for new retail investors,” continued Gillingham. “As we continue to deepen our liquidity, we can provide the best possible price levels across liquidity pools for the institutional investors to price-sensitive retail traders.”

This news follows Finxflo’s recent partnership with Onchain Custodian to provide custody services in preparation to meet updated anti-money laundering (AML) regulation, commonly known as the ‘Travel Rule’. The Travel Rule requires crypto companies to share customer information with each other as part of a transaction. As more and more jurisdictions around the world begin to implement these rules as a prerequisite to obtaining operating licenses, it is imperative for key industry players like Finxflo to have all of the required contingencies in place.

To learn more and explore market pricing, visit: finxflo.com.

Follow them on Twitter, and join the conversation on Telegram.

About Finxflo

Co-founded by leaders in their respective niches, Fearless Legends Pte. Ltd, trading as Finxflo, is a platform that focuses on changing the cryptocurrency market through innovation. As the world’s first hybrid DeFi/CeFi liquidity and protocol aggregator, Finxflo brings a one-stop solution for all cryptocurrency traders and investors. Using only one account with one KYC, our users are now able to utilize liquidity from 25+ various CeFi and DeFi platforms through a single user interface. In simple terms, Finxflo blends all the upsides of DeFi and CeFi ecosystems to produce the ultimate product.

About Crypto.com

Crypto.com was founded in 2016 on a simple belief: it’s a basic human right for everyone to control their money, data and identity. Crypto.com serves over 10 million customers today,  with the world’s fastest growing crypto app, along with the Crypto.com Visa Card – the world’s most widely available crypto card, the Crypto.com Exchange and Crypto.com DeFi Wallet.

Crypto.com is built on a solid foundation of security, privacy and compliance and is the first

cryptocurrency company in the world to have ISO/IEC 27701:2019, CCSS Level 3,

ISO27001:2013 and PCI:DSS 3.2.1, Level 1 compliance, and independently assessed at Tier 4,

the highest level for both NIST Cybersecurity and Privacy Frameworks.

Crypto.com is headquartered in Hong Kong with a 900+ strong team. Find out more by visiting

https://crypto.com

Attachment

• MicrosoftTeams-image

SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) — SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS^® Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS^® Test (abstract number 534) at the American Association for Cancer Research annual meeting, taking place virtually from April 10-15, 2021.

The poster presentation highlighted the utility of the PARIS^® Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in ovarian cancer. In an ovarian cancer cohort of 44 evaluable patient samples, authors found that:

• Ovarian cancer patient-derived 3D cultures preserve the histopathological and molecular features of original tumor samples.
• For 82% of patient samples tested, the PARIS^® Test identified at least one drug with good to exceptional response that is either FDA approved or in clinical trials.
• In 22/24 patient tests (91%), the results demonstrated resistance to at least one drug on which the patient’s disease progressed in clinic.
• The PARIS^® Test showed good clinical response concordant with assay results for 10/12 patients (83%) evaluated for clinical prediction.

This study also presents an example of clinical benefit for a patient with ovarian cancer who received an individualized therapy based on PARIS^® Test results. The patient was diagnosed with stage IV low-grade epithelial serous carcinoma that progressed on multiple rounds of chemotherapies. The patient’s tumor responded to the PARIS^®-guided treatment Ibrutinib, a targeted drug, that to the study authors’ knowledge has never before been employed for ovarian cancer. Ibrutinib is an FDA approved drug only used to treat mantle cell lymphoma and chronic lymphocytic leukemia.

“The PARIS^® Test identified a novel therapy, Ibrutinib, that has successfully controlled the patient’s disease with CA 125 levels dropping by over half during the course of treatment and improvement in her symptoms,” noted Heidi Gray, MD, treating physician in the patient case study presented at AACR 2021. “This is a breakthrough example of the power of phenotypic testing to identify effective treatments for individual patients by scanning a broad menu of oncology drugs.”

“The PARIS^® Test adds a new dimension to precision oncology by confronting patients’ tumor cells with drugs outside the body. By harnessing a unique series of algorithms applied to the results of the PARIS^® Test, drug sensitivity versus resistance is accurately predicted and drug responses are ranked for each patient,” said Carla Grandori, MD, PhD, co-founder and Chief Executive Officer of SEngine Precision Medicine. “Through this case and others, we have learned that cancer is not so strong after all, even when refractory to multiple chemotherapy regimens. Cancers have vulnerabilities that can be exploited by a growing array of targeted drugs. In the case study presented at AACR 2021, the patient’s tumor responded to Ibrutinib, a well-tolerated drug that could potentially help 10% of patients with ovarian cancer.”

“Every patient’s cancer is unique, and we observe distinctive patterns of genomic features and targeted drug responses across patients that highlight the need to individualize therapy. Our data provides compelling evidence that the organ of tumor origin only partially matters for determining effective therapies and that supports the use of a range of existing targeted therapies for ovarian cancer,” commented Goldie Lui, PhD, Lead Scientist at SEngine Precision Medicine and first author of this study.

Details related to the poster presentation are as follows:
Title: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities
Lead Author: Goldie Lui, PhD
Senior Author: Carla Grandori, MD, PhD
Abstract Number: 534
Session Title: Laboratory Correlates for Targeted Agents

About PARIS^® Test 
The PARIS^® Test is based on the capability to propagate patient-specific cancer cells outside the body and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Cancer-derived cells grown in 3D outside the body maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where a treatment path is not clear, such as many metastatic and recurrent cancers, the PARIS^® Test provides crucial information to treating physicians to match the right drug to the right patient.

About SEngine Precision Medicine

SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS^® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with phenotypic testing of patient-derived live cells combined with robotics and AI-driven computational tools. SEngine’s CLIA certified PARIS^® Test generates actionable drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

Contact:

Stephanie Carrington
[email protected]
646-277-1282

“

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION



TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

”

VANCOUVER, British Columbia, April 13, 2021 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to announce that, in response to strong investor demand, it is increasing its non-brokered private placement first announced on March 29, 2021 and initially increased on April 9, 2021 to raise an aggregate of $3,000,000 through exercise of an additional overallotment option.

The Offering price remains $0.18 per Unit, each composed of one Sonoro Common share and one Common share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional Sonoro Common share for a period of two years from the date of closing at an exercise price of $0.30 per share. The Offering, if fully subscribed, will result in the issuance of 16,666,667 shares and 16,666,667 warrants.

Kenneth MacLeod, President and CEO of Sonoro, stated, “The proceeds from the increased private placement will enable our technical teams to complete additional drilling, increasing the results available for consideration in an updated resource estimate, and additional scientific field work and geological structural analysis which will be incorporated into the 43-101 technical report being prepared by Micon International. No further equity financings are anticipated prior to completion of the Preliminary Economic Assessment by D.E.N.M. Engineering, anticipated in summer 2021, which will incorporate the metallurgical testing being conducted by McClelland Laboratories and the 43-101 technical report by Micon.”

The Company intends to pay finder’s fees as permitted under the policies of the TSX Venture Exchange in respect of Units placed with the assistance of registered securities dealers. All securities issued and issuable in connection with the Offering will be subject to a 4-month hold period in Canada from the closing date. The Offering, including the overallotment option, is subject to TSX Venture Exchange acceptance.

The net proceeds from the Offering will be used principally to fund Sonoro’s ongoing development plans at its Cerro Caliche Gold Project located in Sonora, Mexico and project property maintenance payments, and secondarily for corporate and general administrative expenses.

About Sonoro Gold Corp.

Sonoro Gold Corp. is a publicly listed exploration and development company with a portfolio of exploration-stage precious metal properties in Sonora State, Mexico. The Company has highly experienced operational and management teams with proven track records for the discovery and development of natural resource deposits.

For further information, please contact:
Sonoro Gold Corp. – Tel: (604) 632-1764
Email: [email protected]

Forward-Looking Statement Cautions:


This press release contains certain “forward-looking statements” within the meaning of Canadian securities legislation, relating to, among other things: (i) completion of the above-described unit private placement, and the contemplated use of proceeds raised, (ii) completion of the column leach tests, completion of an updated 43-101 resource report and a PEA for the Cerro Caliche project, and (iii) a possible production decision for the Company’s Cerro Caliche project. Although the Company believes that such statements are reasonable based on current circumstances, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties, including the risks that the Company will not be able to successfully sell any or all of the Units; the Company will not be able otherwise to secure the financing necessary to fund its proposed exploration and development of its Cerro Caliche Project, or to fund its other project exploration and development business; future exploration results will be unfavourable and will not support the proposed plan to build a heap leach pilot operation or justify further exploration efforts; equipment failures, accidents, or external problems (e.g. civil unrest, public health emergencies) may materially increase the Company’s business expenses or delay (or prevent altogether) the execution of the Company’s business plans; and unanticipated changes in the legal, regulatory and permitting requirements for the Company’s mineral exploration programs and development plans for its projects, at present, all of which are located in Mexico, may prevent the Company from carrying out some or all of its business plans.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or the policies of the TSX Venture Exchange. Readers are encouraged to review the Company’s complete public disclosure record on SEDAR at
www.sedar.com
for further information regarding the Company’s business and the risks associated therewith.

“This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons, as such term is defined in Regulation S under the Securities Act (“Regulation S”), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act.”

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

• Transaction is anticipated to make ESE one of the largest esports infrastructure companies in the world, bridging esports companies with their fans and customers.
• In 2020, WPG’s assets generated revenue in excess of $14,000,000.
• The Transaction will add WPG’s existing client base to ESE. Clients of WPG’s subsidiary, WPG Racing Solutions, include one of the largest esports companies in the world, and one of the largest sports organizations.
• Acquisition will deliver on core strategic priorities of increasing revenue, expanding tier-1 client base, strengthening technology stack, expanding operational geography, adding experienced executives to ESE’s management, and increasing platform scalability through WPG’s over 100 staff.

VANCOUVER, British Columbia, April 13, 2021 (GLOBE NEWSWIRE) — ESE Entertainment Inc. (TSXV: ESE) (OTCQB: ENTEF) (the “Company” or “ESE”) is pleased to announce that it has closed the previously-announced acquisition of 51% of the business of World Phoning Group Inc., Encore Telecom Inc., and their two European operating subsidiaries, WPG Racing Solutions and Foresight Resolutions (collectively, “WPG”), effective April 12, 2021.

Under the terms of the Agreement, all of the assets of WPG were rolled into a newly incorporated Canadian company, World Performance Group Ltd. (the “Corporation”), and, pursuant to a share purchase agreement dated February 16, 2021 (the “Agreement”), ESE acquired 51% of the issued and outstanding shares of the Corporation (the “Transaction”). The Corporation will carry on the business of WPG following the closing of the Transaction (the “Closing”), which will allow ESE to further develop its robust esports and entertainment infrastructure business.

WPG’s principal, Wayne Silver, has agreed to serve as the Corporation’s CEO to continue to operate WPG’s business and ensure smooth integration of WPG’s infrastructure into ESE’s existing operations. Mr. Silver has also been appointed to ESE’s advisory board.

WPG is an enhanced solutions provider operating an infrastructure business for management of fan engagement for OTT & esports. WPG works with its customers to build new and improved B2C & B2B processes that align with the customer’s brand, boost retention, enhance fan interaction, improve ROI, and increase sales and profit margins. WPG provides bespoke, omni-channel solutions that encompass the traditional esports channels (voice, chat, email) and embrace new contact channels (Discord, Reddit, etc.) and social media used by millennials and many of today’s younger fans. WPG also offers robust out-sourced network services, including B2B and B2C services, and operates a global telecom network through Encore Telecom Inc.

Wayne Silver, CEO of WPG, commented, “Since December 2020, our team has embraced becoming part of the ESE Family, and we’re now pleased to say it’s official. 2021 is off to a tremendous start for WPG. Since January 2021, we have hired over 45 new agents and a senior Operations Manager. This will be key to helping scale our sales efforts. In addition, we have our sights set to expand our geographic offering into the Middle East. With the added support from ESE’s team, we aim to continue to grow both organically and through acquisitions.”

“Our company vision has been clear from the onset – acquire accretive and synergistic companies alongside organic growth to become the largest global esports company. This is now the second completed acquisition for ESE and we anticipate many more to come. From the moment we signed the WPG LOI in December 2020, we began integrating our two great teams. Wayne and the team at WPG are ready to accelerate operations and surpass our already ambitious expansion plan,” said Konrad Wasiela, CEO of ESE.

Transaction Details

The purchase price of the Transaction consisted of: (i) $128,019 in cash paid on Closing; (ii) 585,156 common shares of ESE (each, a “Common Share”) issued on Closing; and (iii) 6,664,845 Common Shares (the “Reverse Vesting Shares”) to be released in monthly installments over the 36 months following the Closing. ESE has also agreed to make an investment of $750,000 in the Corporation to fund its working capital needs.

ESE has the option to acquire the remaining 49% of the issued and outstanding shares of the Corporation (the “Minority Interest”) at any time within 34 months following the Closing by: (i) paying $624,613 in cash; and (ii) issuing 2,500,000 Common Shares. World Phoning Group Inc. and Encore Telecom Inc. (together, the “Vendors”) have the right to sell the Minority Interest to ESE at any time within 34 months following the Closing upon the occurrence of a change of control event (the “Put Option”) in exchange for ESE (i) paying $780,766.88 in cash; and (ii) issuing 3,125,000 Common Shares.

Wayne Silver will act as the Corporation’s CEO pursuant to the terms of an Executive Consulting Agreement (the “Executive Agreement”), which provides, among other things, that Mr. Silver will be entitled to an annual bonus based on the annual audited revenue of the Corporation (the “Performance Bonus”), subject to a limit that the Performance Bonus will be capped at three (3) times Mr. Silver’s annual salary under the Executive Agreement.

If Mr. Silver voluntarily resigns from his position with the Corporation, ESE will have the right to repurchase for cancellation the unreleased portion of the Reverse Vesting Shares as of the date of such resignation for a nominal price. If ESE commits certain material events of default at any time within four (4) years of Closing, the Vendors will have the right to repurchase ESE’s shares in the Corporation at a price established by a formula set out in the Agreement. Such repurchase right will expire four (4) years after Closing. In connection with the Transaction, ESE will issue an aggregate of 435,000 Common Shares to ZDK Holdings Ltd. for providing M&A advisory services in connection with the Transaction.

About ESE

ESE is a Europe based entertainment and technology company focused on gaming, particularly on esports. ESE consists of multiple assets and world-class operators in the gaming and esports industries. Capabilities include physical infrastructure, broadcasting, global distribution for gaming and esports-related content, advertising, sponsorship support, and a growing esports team franchise, K1CK Esports. ESE is focused on bridging Europe, Asia and North America. | www.ese.gg

About WPG

WPG is a Canadian and European based infrastructure business for management of fan engagement for OTT & esports. WPG works with its customers to build new and improved B2C & B2B processes that align with the customer’s brand, boost retention, enhance off-site fan interaction, and improve ROI. WPG provides bespoke, omni-channel solutions, that encompass the traditional channels (voice, chat, email), social media channels (Twitter, Facebook) and embracing new community channels (Discord, Reddit, etc.), used by millennials and many of today’s younger fans and Generation Z. | www.wpgrs.org

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that ESE anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements with respect to (i) the expansion of WPG’s operations geographically; (ii) growing WPG’s business through acquisitions; (iii) the ability to scale WPG’s and ESE’s businesses; (iv) the likelihood of ESE acquiring the Minority Interest; (v) the effect of the Transaction on the parties, including the growth prospects of ESE following the Transaction; and (vi) the anticipated benefits associated with the Transaction. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of ESE to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Among other things, there can be no assurance that the Transaction will be completed or that the anticipated benefits from the Transaction will be achieved. Such factors may be based on information currently available to ESE, including information obtained from third-party industry analysts and other third-party sources, and are based on management’s current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Trading in the securities of ESE should be considered highly speculative.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE ESE Entertainment Inc.
For further information about ESE, please contact:
Daniel Mogil, Investor Relations
[email protected]
647-492-1535

Summit, N.J., April 13, 2021 (GLOBE NEWSWIRE) — Journey Strategic Wealth (“Journey”), a registered investment advisor and practice management partner, today announced the launch of their San Francisco office led by award-winning advisor Kristin Bartlow, CFP®, CLU®, RICP, ChFC®, WMCP®, previously of Bartlow Wealth Management, a Northwestern Mutual firm. The team brings $180M in assets under management to Journey. 

Bartlow’s team includes Brett Agnew, CFP®, Kevin D. Rinow, CFP®, CLU®, RICP®, ChFC®, and Adrienne Braccia Conrad. They are the first advisors to join Journey’s practice management-centric RIA model and will primarily serve institutional and other pre-retirement clients, including high-net-worth technology executives and their families. Bartlow has been recognized by Forbes as a “Top Women Wealth Advisor of 2020” and by Working Mother & Shook Research as a “2020 Top Wealth Advisor Moms” recipient. 

“We are so honored to welcome Kristin’s team into the Journey family and are extremely proud to have them be the new face of our San Francisco office,” said Penny Phillips, president and co-founder of Journey. “When we set out to launch Journey, we had a very specific advisor in mind: a talented leader who is compassionate, who stands up for their clients and what they believe in, and who has an unwavering commitment to their fiduciary duty – this is Kristin, Brett, Kevin, and Adrienne to the nth degree.” 

Journey was founded by longtime advisor executives Michael Brown and Brian Flynn, along with notable advisor practice management coach, Phillips of Thrivos Consulting. The firm is a hybrid RIA model centered on providing hands-on practice management support and coaching to advisory teams who want to focus on serving their clients. Unlike the traditional aggregator model – which is aimed at business growth rather than practice management – Journey’s highly skilled team of experts handles everything from billing, human resources and payroll, investment management, financial planning, technology stack, home office support, and marketing. 

“We are so happy to be joining Journey, supported by a team who understands what is important to us as advisors and ultimately to our clients,” said Bartlow. “The support at every level allows us to better engage with our clients’ financial planning needs while knowing for certain that we’re doing everything necessary to help them find financial freedom. This next chapter is bright.” 

Journey takes an intentional, proactive approach to help advisors best serve their clients, particularly corporate executives, multi-generational families, and ultra-high net worth families. This includes hiring a team with a unique range of experience from all across the financial services industry who can guide clients through full-picture financial planning, investment management, risk analysis, and business or family office planning.

“We’re in the middle of a digital revolution where client expectations are constantly changing,” said Phillips. “When we see an opportunity for our advisors to engage with clients in a new and effective way, you can bet that we’ll make it happen.” 

Journey is headquartered in Summit, N.J., and currently manages $2.7B total client assets. The firm continues to seek advisory teams across the U.S. that align with their clients’ needs and corporate values.

For media inquiries, contact [email protected]. For more information about Journey, visit www.journeysw.com. 

About Journey Strategic Wealth

Journey Strategic Wealth (“Journey”) is a registered investment advisor that works with a broad range of multi-generational clients across the U.S., including corporate executives, high-net-worth individuals, and their families. 

As a hands-on strategic partner to financial advisors, Journey doubles down on consistent practice management support – including billing, human resources and payroll, investment management, financial planning, technology stack, home office support, and marketing. This empowers our advisors to focus on what they came here to do in the first place: financially guide their clients through life’s ups and downs. 

Journey is headquartered in Summit, N.J. with an office in San Francisco. Journey currently manages $2.7B in client assets. 

Advisory services are offered through Journey Strategic Wealth (“Journey”). Securities are offered through Purshe Kaplan Sterling Investments, Inc. (“PKS”). Journey and PKS are not affiliated. Advisory services are only offered to clients or prospective clients where Journey and its representatives are properly licensed or exempt from licensure.

###

Attachments

• Kristin Bartlow Headshot_-1
• Screen Shot 2021-03-29 at 4.26.28 PM

BOULDER, Colo., April 13, 2021 (GLOBE NEWSWIRE) — BDSA, the leader in data, market intelligence and strategic guidance to the cannabis industry, announced today that its cannabis retail sales tracking now includes category-level coverage for the Florida medical market and Michigan adult-use and medical markets. With this release, BDSA’s clients and retail partners will have access to a comprehensive suite of consumer and market insights and analytics in these two states, giving them insights into consumer behaviors, market dynamics, preferences, and more.

“Having insights into the Florida and Michigan markets will provide cannabis investors, retailers and manufacturers with access to significant opportunities as both have enthusiastic and committed consumer populations with a large percentage of cannabis users,” said Micah Tapman, CEO of BDSA. “BDSA’s data will provide our clients with the insights needed to make investment and development decisions and will include information around trending size of the market at a granular category level in addition to consumer understanding and future market sizing already available from BDSA.”

Florida’s medical cannabis market is expected to reach $1.5 billion in sales in 2021, growing 53% over 2020. For comparison, the 2020 medical sales in Arizona were approximately $1.0 billion. With both recreational and medical cannabis expected to be legal in Florida by 2023, BDSA forecasts it will grow to $2.6 billion by 2026.

Michigan’s legal cannabis market is expected to reach $1.2 billion sales in 2021, growing 21% versus 2020. BDSA expects Michigan to have a $1.7 billion market by 2026. Since legalizing cannabis in 2018, 39% of the state’s population has reported consuming cannabis, similar to other more mature legal markets like California.

“Both Florida and Michigan currently fall into the top 10 cannabis markets in the U.S., but we expect them to continue climbing the ranks in the coming years,” said Kelly Nielsen, Vice President of Insights & Analytics at BDSA. “Florida is expected to be the third largest U.S. market come 2026 while Michigan is expected to be the ninth largest in the same time frame.”

About BDSA

BDSA helps businesses improve revenues, reduce innovation risk, and prioritize market expansion with accurate and actionable cannabis market intelligence, consumer research and strategic guidance. The company provides a holistic understanding of the cannabis market by generating insights from point-of-sale data, consumer research, and market-wide industry projections. Retailers, manufacturers, brands, wholesalers and investors can now make better strategic decisions that drive profitability, increase revenues and market share, and reduce expenses. BDSA is headquartered in Boulder, Colorado. To learn more please visit www.bdsa.com.

Media Contact

Katie Parr
UPRAISE Marketing + PR for BDSA
415-397-7600
[email protected]

TAMPA, Fla., April 13, 2021 (GLOBE NEWSWIRE) — IVANS®, a division of Applied Systems®, today announced that SLB Insurance Group has selected IVANS Markets to automate appetite communications to more than 33,000 agencies within the IVANS network. IVANS Markets will enable the wholesaler to market its appetite directly within agents’ daily workflows at the moment they search for a risk, supporting agency demand for enhanced connectivity and creating new premium opportunities through increased agency awareness.

“The independent agency channel is a critical part of our distribution strategy, so we want to ensure our appetite is front and center where our current and prospective agencies operate day to day,” said Kyle Friedman, underwriter, SLB Insurance Group. “IVANS Markets allows us to market our appetite directly in agents’ management systems, making sure we are consistently showing up at the point of opportunity to more agencies within the IVANS network.”

IVANS Markets provides insurers and MGAs an industry-first application to instantly communicate appetite and identify new business opportunities in the IVANS network of more than 33,000 independent insurance agencies. Leveraging this digital channel also reduces dependency on time-consuming, manual steps traditionally used to communicate appetite. IVANS Markets increases in-appetite submissions to drive growth and profitability.

“In today’s digital world, the traditional ways of communicating appetite, such as printed guides or person-to-person interactions, are too cumbersome to manage and can result in inaccurate information,” said Kathy Hrach, vice president of Product Management, IVANS Insurance Solutions. “IVANS Markets automates appetite communications and enables SLB Insurance Group to meet agencies where they are, instantly increasing awareness and creating greater opportunity for conversion.”

The IVANS logos are trademarks of Applied Systems, Inc., registered in the U.S.

About IVANS

IVANS, a division of Applied Systems, is the insurance industry’s exchange connecting insurers, MGAs, agencies, and the insured. IVANS cloud-based software automates the distribution and servicing of insurance products. For more than 35 years, IVANS innovation and expertise has connected 32,000 independent insurance agencies and 400 insurer and MGA partners to enable millions of people to safeguard and protect what matters most in people’s lives.

WESTMINSTER, Colo., April 13, 2021 (GLOBE NEWSWIRE) — We are developing the infrastructure of a global zoonotic infectious diseases “alert shield” (ZIDAS) able to successfully manage and control the COVID-19 pandemic; and ultimately prevent future pandemics from developing. This alert shield will operate like a “nuclear shield,” designed to detect incoming nuclear warheads and destroy them before they can be deployed. A global network of AI controlled laboratory robotic systems, capable of collecting, storing and analyzing data, will be able to perform such a task.

We envision two types of laboratory settings:

The first, stationary integrated robotic lab facilities designed for ultra high throughput, capable to processing 100,000-200,000 samples/lab/day. Samples will be collected from the general population and sent to the labs to be tested. These facilities will be also focus on growing viral strains for R&D and new anti-viral therapeutics development for SARS-CoV-2 and other potential pandemic viruses

Mobile integrated robotic lab units will be designed as a scaled- down version of the ultra-high throughput platform described above. Each mobile unit will be equipped with an integrated robotic system capable to perform 2,000-4,000 samples/units/day. Electric vehicles represent the ideal solution to the development of this network of mobile labs designed to test wastewater from reclamation plants.

Dr. Tony Milici, Chairman & CEO of GeneThera (OTC: GTHR), commented: “We believe that the implementation of SMART TESTING TECHNOLOGY (STT) could change the course of the COVID pandemic and predict future pandemic before they developed. It is quite clear that performing massive number of testing using unreliable or non standardized technology does not control the virus or provide scientists the information needed to understand the spread of the virus and the insurgence of new potentially dangerous strains. It is still unclear whether or not vaccines will be able to stop the COVID. https://www.detroitnews.com/story/news/local/michigan/2021/04/05/246-vaccinated-residents-diagnosed-covid-3-dead-michigan/7100759002/

Additionally mass vaccination is creating a false sense of safety within the general population in part due widespread media misinformation among other variables. As result, the number of tests being performed is declining. Consequentially wastewater testing has became even more important to detect the rate of viral infection in the human population and specific communities. Presently most diagnostic and university labs are only capable of processing a low number of wastewater samples daily. GeneThera’s plan to deploy mobile robotic laboratories units capable of processing on location, thousand of wastewater samples using Smart Testing Technology will be a critical component of our ZIDAS surveillance system platform. This technology should be able to analyze the spread of the virus within communities and discover the presence of new viral variances before they would infect the general population. Our ultimate goal is to deploy tens of thousands of mobile lab units capable of processing thousand of samples worldwide using vehicles that can last for decades with extraordinary little maintenance.”

About GeneThera, Inc.

GeneThera is a biotechnology company developing molecular robotic/AI diagnostics and therapeutics in an effort to control and eradicate zoonotic diseases. GeneThera developed molecular assays for BSE and Mycobacterium Avium Paratuberculosis (MAP). MAP is an infectious organism causing Paratuberculosis in dairy cows that is also linked to Crohn’s Disease in humans. We utilize these technologies to minimize the spread of animal infectious organisms such as SARS-CoV-2 to humans. Management and prevention of zoonotic diseases is crucial to human and animal health on a global scale.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends,” “believes,” and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

For further information please contact:

Tony Milici MD, Ph.D.
GeneThera Inc.
720 587-5100

MARKHAM, Ontario, April 13, 2021 (GLOBE NEWSWIRE) — Amfeltec Corporation announced today that it’s new 2U PCI Express Gen 3 SSD Board is in full production. This is the latest addition to Amfeltec’s Arowana PCI Express SSD Board Family(TM).

“The trend to move from mechanical hard drives to SSD affects many sectors, including industrial and automotive. Our Arowana PCIe SSD Board Family will equip players in those sectors with the first extremely fast and ruggedized storage solution,” said Michael Feldman, President and CTO at Amfeltec Corp. “The reason our new Arowana board is the fastest on the market is because it incorporates up to eight independent x4 PCI express Gen 3 SSDs. They can be combined in a RAID to reach a read and write speed of over 11.8 Gb/sec.”

It is a one-slot-wide, half-height (2U), half-length PCI Express Gen 3 SSD Board with a storage capacity of 8 TB (optionally 4 TB), and industrial or automotive operation rates (-40°C to +95°C, and -40°C to +105°C, respectively).

The SSD board has a solid design, and connects to the motherboard via exchangeable male x16 PCI Express adapters (optionally x8). This allows the SSD board to be inserted into different sizes of PCI Express connectors without encountering well-known limitations (US Pat. #9,996,495; US Pat. #10,664,431).

This board’s thermal design is based on the combination of two anodized aluminum heatsinks, located on both sides of the board (top and bottom). An additional bottom heatsink has an optional low-noise fan with a self-adjusting operation speed. This fan allows for board deployment to locations where the air flow is poor or obstructed.

The board also has real-time performance and temperature monitoring capability (US Pat. # 10,481,660).

Arowana
PCI Express SSD Boards operate on any motherboard, and do not require motherboard bifurcation support.

Arowana
Family currently includes the following PCIe SSD boards:

For additional information, please visit the product page: https://www.amfeltec.com/industrial-pci-express-ssd-board/

About Amfeltec Corporation:

Amfeltec is a Canadian company, incorporated since 2005. It is a leading provider of complex and innovative solutions for the world’s diverse electronics markets. Amfeltec specializes in electronic engineering, with emphasis on high-speed interconnect technologies, a large variety of computer hardware expansion products, telecommunications connectivity products, and testing & production tools.
All Amfeltec products are manufactured in Canada, and most are covered by one or more United States patents.